NCT03338062 A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy Status COMPLETED Phase NA
NCT03329950 A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT03250273 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Status COMPLETED Phase PHASE2
NCT03219268 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Status COMPLETED Phase PHASE1
NCT03211169 Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Status TERMINATED Phase NA
NCT03207347 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Status COMPLETED Phase PHASE2
NCT03172832 A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors Status TERMINATED Phase NA
NCT03144661 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Status TERMINATED Phase PHASE1
NCT03140007 Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic . Status UNKNOWN Phase NA
NCT03111732 Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Status COMPLETED Phase PHASE2
NCT03079427 Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Status COMPLETED Phase PHASE2
NCT03042182 Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma Status UNKNOWN Phase PHASE1/PHASE2
NCT03041662 Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC) Status COMPLETED Phase N/A
NCT03027284 A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Status COMPLETED Phase PHASE1